Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × vatalanib × Breast × Clear all
NCT00268918 2018-07-27

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00216047 2015-12-09

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Hoosier Cancer Research Network

Phase 1/2 Terminated
7 enrolled
Breast

Breast Neoplasms

NCT00263198 2013-05-07

PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer

Washington University School of Medicine

Phase 2 Terminated
4 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡